ABEO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.342

+144.05%

-0.130

-45.83%

-0.113

-106.63%

Estimates Revision

The market is revising Downward the revenue expectations for Abeona Therapeutics Inc. (ABEO) for FY2025, with the revenue forecasts being adjusted by -78.03% over the past three months. During the same period, the stock price has changed by -9.30%.

Revenue Estimates for FY2025

Revise Downward

-78.03%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-6.16%

In Past 3 Month

Stock Price

Go Down

-9.30%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast ABEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABEO is 22.17 USD with a low forecast of 19.00 USD and a high forecast of 27.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

19.00

Averages

22.17

High

27.50

Current: 0.000

Low

19.00

Averages

22.17

High

27.50

Stifel

Stephen Willey

Buy

downgrade

$20 -> $19

2025-11-12

Reason

Stifel

Stephen Willey

Price Target

$20 -> $19

2025-11-12

downgrade

Buy

Reason

Stifel analyst Stephen Willey lowered the firm's price target on Abeona Therapeutics to $19 from $20 and keeps a Buy rating on the shares. Management's temporary pause on patient biopsy collection sets back the commercial launch by about three months and decreases confidence in the firm's now-lower Q4 estimate as a result of the temporal uncertainty associated with the timing of revenue recognition, the analyst tells investors in a research note. The firm added that increasing patient demand strengthens its confidence in FY26 and beyond, and believes the set-up here offers an attractive risk/reward.

Oppenheimer

Outperform

maintain

$19 -> $20

2025-08-15

Reason

Oppenheimer

Price Target

$19 -> $20

2025-08-15

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Abeona Therapeutics to $20 from $19 and keeps an Outperform rating on the shares following quarterly results and business update highlighting launch progress for Zevaskyn, after the FDA approval in April. Q2 ending cash was bolstered by the sale of Abeona's PRV during the quarter for $155M, ending Q2 with $226M.

Oppenheimer

Outperform

initiated

$19

2025-06-02

Reason

Oppenheimer

Price Target

$19

2025-06-02

initiated

Outperform

Reason

Oppenheimer assumed coverage of Abeona Therapeutics with an Outperform rating and $19 price target. The firm notes Abeona's Q1 update highlighted strong early momentum following ZEVASKYN's April approval. The first Qualified Treatment Center has been activated ahead of schedule with the first patient on track for treatment in Q3 2025. Enthusiasm from patients/caregivers and physicians remains high. Notably, management highlighted strong interest at the SID conference, Oppenheimer adds. Based on the early launch progress, the firm's confidence in ZEVASKYN's commercial trajectory is reaffirmed.

Stifel

Stephen Willey

Buy

downgrade

$21 -> $20

2025-05-16

Reason

Stifel

Stephen Willey

Price Target

$21 -> $20

2025-05-16

downgrade

Buy

Reason

Stifel analyst Stephen Willey lowered the firm's price target on Abeona Therapeutics to $20 from $21 and keeps a Buy rating on the shares. The firm views the recent activation of the first Zevaskyn Qualified Treatment Center and the anticipated treatment of the first patient in August 2025 as "an encouraging development," the analyst tells investors in a Q1 recap note.

Alliance Global Partners

analyst

Buy

maintain

$25

2025-05-15

Reason

Alliance Global Partners

analyst

Price Target

$25

2025-05-15

maintain

Buy

Reason

Alliance Global Partners raised the firm's price target on Abeona Therapeutics to $27.50 from $25 and keeps a Buy rating on the shares. Abeona announced Q1 results following the recent news of their FDA approval for Zevaskyn, a gene therapy for recessive dystrophic epidermolysis bullosa, notes the analyst, who also points out that the company recently entered into an agreement to sell the Rare Pediatric Disease Priority Review Voucher it was granted for $155M, allowing for additional funding. The firm values Zevaskyn for RDEB at $24 per share and the remaining pipeline, which includes ABO-102 for Sanfilippo syndrome and three preclinical programs, and cash at $3.50 per share.

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

$15

2025-03-24

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$15

2025-03-24

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Abeona Therapeutics Inc (ABEO.O) is -8.63, compared to its 5-year average forward P/E of -0.23. For a more detailed relative valuation and DCF analysis to assess Abeona Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.23

Current PE

-8.63

Overvalued PE

28.82

Undervalued PE

-29.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

175.15

Current PS

3.78

Overvalued PS

430.07

Undervalued PS

-79.76

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ABEO News & Events

Events Timeline

No data

News

6.5

01-01Yahoo Finance

Analysis of High Insider Ownership Growth Companies in the U.S.

5.0

2025-12-31Globenewswire

Abeona Grants 79,584 Restricted Stock Awards to New Employees

5.0

2025-12-31Newsfilter

Abeona Grants 79,584 Restricted Stock Awards to New Employees

People Also Watch

Frequently Asked Questions

What is Abeona Therapeutics Inc (ABEO) stock price today?

The current price of ABEO is 5.025 USD — it has decreased -3.74 % in the last trading day.

What is Abeona Therapeutics Inc (ABEO)'s business?

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).

What is the price predicton of ABEO Stock?

What is Abeona Therapeutics Inc (ABEO)'s revenue for the last quarter?

Abeona Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Abeona Therapeutics Inc (ABEO)'s earnings per share (EPS) for the last quarter?

Abeona Therapeutics Inc. EPS for the last quarter amounts to -0.10 USD, decreased -84.13 % YoY.

What changes have occurred in the market's expectations for Abeona Therapeutics Inc (ABEO)'s fundamentals?

How many employees does Abeona Therapeutics Inc (ABEO). have?

Abeona Therapeutics Inc (ABEO) has 136 emplpoyees as of January 08 2026.

What is Abeona Therapeutics Inc (ABEO) market cap?

Today ABEO has the market capitalization of 279.63M USD.